Pharma Plant Setup Cost Calculator

Where Revised Schedule M stands, and what it means for a new build

Revised Schedule M was notified through G.S.R. 922(E) dated 28 December 2023[1]. G.S.R. 127(E), dated 11 February 2025, allowed eligible small and medium manufacturers with turnover below ₹250 crore to seek an extension until 31 December 2025 by submitting the required application and upgradation plan[2]. The applicable implementation and enforcement position depends on the manufacturer’s category and whether the extension process was followed. Confirm the current position with CDSCO and the relevant State Licensing Authority.

For a new build the practical consequence is simpler than for an existing unit: Revised Schedule M is the Indian GMP text a new plant is designed and licensed against, so the domestic baseline in the calculator above assumes it. If you already operate a unit and are pricing an upgrade rather than a new build, the Revised Schedule M compliance dashboard scores readiness across the twelve areas inspectors look at.

Compliance standard is the dominant cost variable

The same plant — same sections, same capacity, same state — can differ several-fold purely on the standard it is built to. It is worth being precise about why, because the popular explanation, that export-grade machines simply cost many times more, is only part of the story and is not something a buyer can verify from a price list.

What genuinely changes as you move from Revised Schedule M to WHO-GMP[3], then to EU-GMP[4] and a US-market-oriented design basis[6] is a stack of things that each carry capital cost: tighter cleanroom classification and therefore heavier HVAC and filtration; more instrumented and automated equipment with full material-of-construction documentation; electronic records and data integrity capability across every system that generates GMP data; a far larger qualification and validation programme; wider corridors and airlocks for segregation and personnel flow; and a QC laboratory carrying analytical instrumentation of a different order.

Sterile products carry an additional design layer. For sterile manufacture specifically, the EU GMP Annex 1 revision published on 25 August 2022 and in operation from 25 August 2023, with the lyophilisation provision at point 8.123 deferred to 25 August 2024, makes a documented contamination control strategy and barrier technology an explicit design expectation rather than a preference[5]. That applies to injectables and other sterile dosage forms; it does not govern oral solids or liquid orals.

The multipliers used in the calculator above are Laafon’s own project-rate basis derived from projects we have costed, not a published benchmark. Cleanroom civil work runs at roughly ₹2,500 per sq ft for a Revised Schedule M finish, ₹3,000 for WHO-GMP, ₹5,000 for EU-GMP and ₹8,000 for a US-market-oriented design basis, and the equipment and laboratory packages step up alongside. Treat the Schedule M and WHO-GMP figures as reasonably firm and the EU-GMP and US-oriented figures as indicative, with a wider band, because at that end the spread between two credible vendor lists is genuinely large.

One thing the US-oriented tier is not. Building to a US-market-oriented design basis is a design and capital decision only. It is not a certification, an accreditation, or any guarantee of USFDA approval — that depends on the marketing application, the outcome of facility inspection, and sustained compliance thereafter. The tier exists here so you can size the capital gap before deciding whether to pursue that route, not to imply the route is secured by spending the money.

Capacity matters less than most promoters expect

Doubling output does not double machinery cost. Beyond a base configuration, only the higher-capacity machines change — the rest of the line, the AHU and most of the classified area stay as they are. The increase we observe is roughly 20 to 40 per cent for a doubling of capacity, which the calculator applies as a scaling curve rather than straight multiplication.

The practical implication: if you are choosing between 5 lakh and 10 lakh tablets per day, the larger line is almost always better on cost per unit — provided the market absorbs the output. If it does not, the cheaper route to volume is usually someone else’s line, which is what third-party manufacturing exists for.

Section packages, not machine lists

Each section carries three linked costs: machinery, its dedicated AHU, and its classified area. A tablet section at 5 lakh per day needs about 7,000 sq ft classified; capsules at the same output about 4,000; liquid orals around 7,000; dry syrup 3,000; ointments and creams 2,500; and sterile injectables about 5,000 sq ft with a far heavier machinery and AHU load. Beta-lactam tablet sections match non-beta on machinery but need a heavier dedicated AHU, because segregation of penicillins and cephalosporins is not negotiable under any of these standards.

Land is smaller than most promoters assume

Greenfield land requiring industrial conversion runs roughly ₹150 to ₹400 per sq ft across the main pharma states — Himachal Pradesh (Baddi, Solan, Una) and Uttarakhand (Haridwar, Roorkee) around ₹300, Gujarat lower, Haryana higher. Change of Land Use charges add roughly 5 per cent of land value, though the rate and the process are state-specific and should be confirmed with the local authority before it goes into a funding plan. On most projects land ends up under 10 per cent of total cost — which is why optimising location for vendor access, effluent infrastructure and skilled manpower usually beats optimising for cheap land.

Worked examples

Calculated on the same model this page runs, excluding land so they stay comparable:

Scroll the table sideways on a phone

And the comparison that matters most — one plant, tablets plus capsules in Himachal Pradesh excluding land, across all four grades:

Scroll the table sideways on a phone

The step from Schedule M to WHO-GMP is modest — largely AHU specification and cleanroom finish, since the underlying GMP principles are closely aligned. The step to EU-GMP or a US-market-oriented basis is a different order of investment, and should be underwritten by a committed export order book rather than optimism. Those two rows carry a wider uncertainty band than the first two, and the calculator reflects that in its planning range.

What sits outside this estimate

The calculator covers capital cost to commissioning plus a six-month working capital float. It does not model revenue, break-even, loan servicing, API procurement or product-specific costs. For funding structure, subsidies and payback expectations, read our companion guide to pharma manufacturing plant investment in India, which covers capex bands, the PLI scheme and financing. And if buying an existing licensed unit is faster than building one, compare verified plants for sale and rent before you commit to a greenfield timeline.